Yes, Honeydew's board-certified dermatologists prescribe and manage Rinvoq entirely online. No in-person office visit is required. You complete a medical questionnaire covering your eczema history, previous treatments, and health background, and a licensed dermatology provider reviews your case to determine whether Rinvoq is appropriate given your specific situation and risk profile.

Because Rinvoq requires baseline screening before starting, your Honeydew provider will order any necessary labs and review results before prescribing. From there, we handle prior authorization with your insurance, coordinate the specialty pharmacy, and manage all ongoing monitoring and refills, all online.

Your care team is available seven days a week for any questions during treatment, and your provider will check in regularly to monitor your response, review lab results, and adjust your care plan as needed.

Yes, Rinvoq is FDA-approved for adolescent patients ages 12 and older with moderate to severe atopic dermatitis that hasn't been adequately controlled with other systemic treatments. The standard dose for adolescents is 15mg once daily, the same as the adult starting dose.

The same safety screening and monitoring requirements that apply to adults apply to adolescent patients, including TB screening, baseline labs, and ongoing bloodwork. Rinvoq's black box warning applies to this age group as well, and your Honeydew provider will review your child's full health history and assess the risk-benefit profile before prescribing.

For patients under 18, a parent or guardian must be present for the initial Honeydew consultation. If your teenager has moderate to severe eczema that hasn't responded adequately to topical treatments or biologics, Rinvoq may be worth discussing with a Honeydew dermatologist.

Common side effects of Rinvoq in clinical trials for eczema include upper respiratory infections, acne, nausea, headache, and elevated blood lipids. Most common side effects are mild and manageable. Acne is one of the most frequently reported and distinctive side effects. It's related to Rinvoq's JAK inhibition mechanism and typically appears on the face, chest, or back. In most patients it's mild and can be managed with topical treatments if needed.

More serious side effects to watch for and report to your Honeydew provider promptly include signs of infection (fever, chills, muscle aches, difficulty breathing, warm or painful skin), symptoms of blood clots (pain, swelling, or warmth in a leg; sudden shortness of breath; chest pain), and any unusual lumps or skin changes that persist.

Live vaccines should not be given while on Rinvoq, and your provider will advise on completing any needed vaccinations before starting treatment. If you develop any active infection during treatment, contact your Honeydew care team promptly. Your provider may recommend pausing Rinvoq until the infection resolves.

Because Rinvoq affects immune function and carries warnings related to infection, cardiovascular risk, and malignancy, it requires both baseline screening before starting treatment and ongoing monitoring during treatment. Here's what's typically required:

Before starting Rinvoq: Your Honeydew provider will order baseline labs including a complete blood count (CBC), liver function tests, lipid panel, and kidney function. Tuberculosis (TB) screening is required (either a TB skin test or blood test) and any latent TB must be addressed before starting. Your provider will also review your vaccination history and cardiovascular risk profile.

During treatment: Ongoing monitoring includes periodic CBC, lipid levels, and liver function, particularly during the first several months. Your provider will monitor for signs of infection, unusual bruising or bleeding, and symptoms that could indicate cardiovascular events.

Honeydew coordinates all required lab work on your behalf. We can order labs to a location convenient for you, review results, and adjust your care plan accordingly, all online. The Rinvoq Complete Savings Card also covers related lab monitoring costs up to $1,000 per year for eligible commercially insured patients, reducing the out-of-pocket burden of this required monitoring.

Rinvoq for atopic dermatitis is available in two doses: 15mg and 30mg, both taken once daily.

The standard starting dose for most adults with moderate to severe atopic dermatitis is 15mg once daily. This is the dose used in the LEVEL UP head-to-head trial against Dupixent, and it's the most commonly prescribed dose for eczema. In clinical trials, 15mg Rinvoq showed strong and rapid improvements in both skin clearance and itch reduction.

The 30mg dose is available for patients who need stronger efficacy or who haven't achieved adequate response at 15mg, and is used more selectively given its stronger immunosuppressive effect and corresponding higher safety monitoring requirements.

For adolescents (ages 12 to 17), the starting dose is 15mg once daily, consistent with the adult starting dose.

Your Honeydew dermatologist will determine the appropriate starting dose based on your disease severity, overall health, and any risk factors identified during baseline screening. Rinvoq is taken as an extended-release tablet. It should be swallowed whole, not crushed or cut, and can be taken with or without food.

JAK inhibitors and biologics are both systemic treatments that reduce the immune system activity driving eczema, but they work at different points in the inflammatory process and are delivered differently.

Biologics like Dupixent, Adbry, and Ebglyss, are large protein molecules injected under the skin. They work outside immune cells, blocking specific inflammatory proteins (cytokines like IL-4, IL-13, or IL-31) from binding to their receptors on the cell surface. Each biologic targets one or two specific signaling proteins.

Rinvoq is a JAK inhibitor: a small molecule pill that works inside immune cells by blocking JAK enzymes. JAK enzymes are the internal switches that activate inflammatory signaling across multiple pathways simultaneously. By blocking JAK1 specifically, Rinvoq shuts down several inflammatory signals at once rather than targeting a single cytokine. This broader reach is why Rinvoq produces faster itch relief and stronger skin clearance in head-to-head trials against Dupixent, but also why it requires more careful safety monitoring, since it affects a wider range of immune activity.

The practical summary: biologics are injected every few weeks and block specific inflammatory signals from outside the cell. Rinvoq is a daily pill that blocks inflammatory signaling from inside the cell across multiple pathways. Both are legitimate options for moderate to severe eczema. The right choice depends on your health history, severity, and treatment goals.

Yes, given its list price of over $7,000 per month, Rinvoq requires prior authorization from virtually all insurance plans before coverage is approved. Many plans also require step therapy documentation showing that other systemic treatments, including biologics like Dupixent, were tried and failed before a JAK inhibitor is approved.

Honeydew handles the prior authorization process entirely on your behalf. Your provider prepares and submits all required documentation, follows up with your insurer, and coordinates with the specialty pharmacy to minimize delays. If your initial authorization is denied, we guide you through the appeals process and help you access the Rinvoq Complete Savings Card or myAbbVie Assist program in the interim so treatment doesn't stall while coverage is resolved.

The documentation required for Rinvoq prior authorization, including records of prior biologic use and treatment response, is exactly the kind of medical history review and administrative work that Honeydew manages as part of your ongoing care.

Yes, and this is actually one of Rinvoq's primary FDA-approved use cases. Rinvoq is specifically indicated for adults and adolescents 12 and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

In plain terms: if you've tried Dupixent, Adbry, Ebglyss, or another systemic treatment for eczema and haven't achieved adequate control, Rinvoq is the FDA-approved next step, not a last resort, but a specifically designed option for this situation. In the LEVEL UP trial, Rinvoq was studied in exactly this population and demonstrated superiority over Dupixent in patients who had already had inadequate responses to systemic therapy.

If you're currently on Dupixent and experiencing continued breakthrough flares, persistent itching, or incomplete skin clearance, mention this specifically during your Honeydew consultation. Your provider will assess whether switching to or adding Rinvoq is appropriate for your situation.

Rinvoq and Dupixent are the two most-compared treatments for moderate to severe eczema, and both are prescribed by Honeydew's dermatologists. In a landmark head-to-head Phase 3b/4 trial called LEVEL UP, the largest direct comparison of these two medications to date, Rinvoq demonstrated superiority over Dupixent across the primary endpoint and all key secondary endpoints.

Efficacy: At week 16, 40.8% of patients on Rinvoq achieved nearly clear skin (EASI-90) compared to 22.5% for Dupixent. For itch specifically, Rinvoq also showed stronger and faster reductions. Rinvoq acts more broadly on JAK signaling pathways, which may explain its faster onset and stronger clearance rates, particularly for itching, where improvement is often reported within days to weeks.

Mechanism: Dupixent is a biologic: a protein-based injection that blocks IL-4 and IL-13, two specific inflammatory signals. Rinvoq is a JAK inhibitor: a small molecule pill that blocks JAK1, an intracellular enzyme that regulates multiple inflammatory pathways simultaneously. The broader mechanism of Rinvoq produces stronger itch and skin clearance results in head-to-head trials.

Administration: Dupixent is a subcutaneous injection given every 2 to 4 weeks. Rinvoq is a once-daily oral pill, no injections required.

Safety profile: This is where they differ meaningfully. Dupixent's most common side effects are conjunctivitis and injection site reactions. Rinvoq carries a black box warning covering serious infections, cardiovascular events, malignancies, and blood clots; risks that require baseline screening and ongoing monitoring. The rate of serious adverse events was 0.9% in both arms of the LEVEL UP trial, but the nature of the potential risks differs and Rinvoq requires more intensive safety oversight.

Who is prescribed which: Dupixent is typically the first biologic tried for moderate to severe eczema. Rinvoq is FDA-approved specifically for patients with refractory eczema that hasn't responded adequately to other systemic treatments including biologics making it a natural next step for Dupixent partial responders or non-responders. Your Honeydew dermatologist will recommend which is the better fit based on your eczema severity, treatment history, age, and overall health profile.

Yes, upadacitinib is the generic (scientific) name for Rinvoq. You may see "upadacitinib" on your prescription label, insurance paperwork, or explanation of benefits. It is the same medication. Rinvoq is the brand name manufactured by AbbVie.

Upadacitinib is a JAK inhibitor: specifically a selective JAK1 inhibitor. It works by blocking JAK1, a signaling enzyme inside immune cells that activates the inflammatory pathways responsible for eczema's itching, redness, and skin barrier breakdown. There is currently no FDA-approved generic version of upadacitinib available in the United States.

Yes, Rinvoq carries an FDA black box warning, the most serious safety warning the FDA issues. It covers five areas: serious infections, mortality, malignancies (cancers), major adverse cardiovascular events, and thrombosis (blood clots). This sounds alarming, and it's worth understanding clearly what the warning reflects and how it applies to eczema patients specifically.

The black box warning was largely informed by data from a large postmarketing study of a different JAK inhibitor (tofacitinib/Xeljanz) in older rheumatoid arthritis patients, a population with significantly higher baseline cardiovascular and cancer risk than most people with moderate to severe eczema. The FDA applied a class-wide warning to all JAK inhibitors as a precaution, including Rinvoq for eczema, even though the eczema patient population is generally younger and carries lower baseline risk for these events.

In clinical trials of Rinvoq specifically for atopic dermatitis, the rate of serious adverse events was 0.9%, identical to the Dupixent comparator arm in the LEVEL UP head-to-head trial. That doesn't mean the risks are zero, but it provides important context.

What this means practically: Rinvoq is not appropriate for all patients. Before prescribing it, your Honeydew dermatologist will review your complete health history including any history of cancer, cardiovascular disease, blood clots, active smoking, or significant infections, and screen for tuberculosis. Patients who are current or past smokers, are over 50 with cardiovascular risk factors, or have a history of certain cancers may not be appropriate candidates for Rinvoq. Your provider will discuss your individual risk profile before prescribing.

If you are an appropriate candidate, Rinvoq can be a highly effective option for severe eczema but it requires close ongoing monitoring, which Honeydew manages on your behalf throughout treatment.

Rinvoq's list price is $7,090 for a 30-day supply, one of the highest list prices among eczema treatments, but most patients pay significantly less, and many pay $0. Here's how the savings programs break down:

With commercial insurance: Eligible patients can enroll in the Rinvoq Complete Savings Card, which may cover the complete monthly cost of your prescription, bringing your out-of-pocket cost to $0 per month. The program also covers related lab monitoring costs up to $1,000 per year, a meaningful benefit given Rinvoq requires baseline and ongoing blood work. Honeydew handles insurance verification and prior authorization on your behalf before you start, so coverage is confirmed upfront.

Without commercial insurance: The myAbbVie Assist patient assistance program provides Rinvoq at no cost for eligible uninsured, underinsured, or low-income patients. Qualified applicants can receive Rinvoq for free with no copays or shipping fees, renewable after the initial period. To apply, you complete an enrollment form through your Honeydew provider.

Note that the Rinvoq Complete Savings Card is not available to patients covered by Medicare, Medicaid, VA, or other government-funded programs. If you have Medicare Part D coverage, as of January 1, 2026 all Medicare Part D patients pay no more than $2,100 per year in covered out-of-pocket costs, a meaningful cap for a medication at this price point. Your Honeydew care team can connect you with an AbbVie insurance specialist to help navigate your specific plan.

Honeydew's membership fee (starting at $25/month on an annual plan) is separate from medication costs and is HSA/FSA eligible. We handle prior authorization, pharmacy coordination, and insurance navigation on your behalf throughout treatment.

If you or your child is under the age of 18, a parent or guardian should be part of the initial consultation. In circumstances where this is not possible, please contact info@honeydewcare.com and we will assist you with alternate ways to establish parental consent.

We will run the prescriptions through your insurance and help you find the lowest costs out there. The membership fee and any products are also eligible for HSA or FSA reimbursement.

We offer comprehensive support for our patients, including access to experienced providers, assistance with lab orders and the iPledge program (when needed), unlimited support, and progress tracking.